14-day Premium Trial Subscription Try For FreeTry Free
HK$1.58
+0.0800 (+5.33%)
At Close: Jun 14, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions Profile
There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:
Click to get the best stock tips daily for free!

About Hua Medicine (Shanghai) Ltd.

Hua Medicine (Shanghai) Ltd. Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone fo... 2552.HK Profile

Golden Star

Ticker Date Change Price
LIN Jun 12 0.640% $434.17
BNDX Jun 12 0.637% $48.64
MAIN Jun 12 0.673% $49.01
EQR Jun 11 1.77% $65.55
RPM Jun 11 0.92% $110.28
FR Jun 11 1.52% $46.78
CAH Jun 11 1.20% $99.01
ESI Jun 11 11.50% $23.73
FTGC Jun 11 0.374% $24.09
FTSM Jun 11 0.0838% $59.68
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT